AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE

N/A

Manufactured by Kenvue Brands LLC

448 FDA adverse event reports analyzed

Last updated: 2026-04-15

About AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE

AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Kenvue Brands LLC. The most commonly reported adverse reactions for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE include SKIN CANCER, BASAL CELL CARCINOMA, NEOPLASM MALIGNANT, RASH, MALIGNANT MELANOMA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE.

Top Adverse Reactions

SKIN CANCER58 reports
BASAL CELL CARCINOMA21 reports
NEOPLASM MALIGNANT21 reports
RASH21 reports
MALIGNANT MELANOMA19 reports
DRUG INEFFECTIVE13 reports
PRODUCT LOT NUMBER ISSUE12 reports
RECALLED PRODUCT ADMINISTERED11 reports
BURNS THIRD DEGREE10 reports
PRODUCT EXPIRATION DATE ISSUE10 reports
SUNBURN10 reports
PRURITUS9 reports
SQUAMOUS CELL CARCINOMA8 reports
BREAST CANCER7 reports
APPLICATION SITE BURN6 reports
APPLICATION SITE ERYTHEMA6 reports
APPLICATION SITE PAIN6 reports
APPLICATION SITE RASH6 reports
BLISTER6 reports
HYPERSENSITIVITY6 reports
PRECANCEROUS SKIN LESION6 reports
RASH PRURITIC6 reports
URTICARIA6 reports
APPLICATION SITE REACTION5 reports
ERYTHEMA5 reports
SKIN EXFOLIATION5 reports
ACUTE MYELOID LEUKAEMIA4 reports
ADVERSE EVENT4 reports
APPLICATION SITE SWELLING4 reports
COUGH4 reports
DRY SKIN4 reports
EXPIRED PRODUCT ADMINISTERED4 reports
PRODUCT QUALITY ISSUE4 reports
RASH ERYTHEMATOUS4 reports
ACCIDENTAL EXPOSURE TO PRODUCT3 reports
APPLICATION SITE HYPERSENSITIVITY3 reports
APPLICATION SITE IRRITATION3 reports
APPLICATION SITE SCAR3 reports
DYSPNOEA3 reports
PHOTOSENSITIVITY REACTION3 reports
PRODUCT CONTAMINATION CHEMICAL3 reports
PRODUCT LABEL ISSUE3 reports
SKIN BURNING SENSATION3 reports
SKIN DISCOLOURATION3 reports
SWELLING FACE3 reports
ANGIOEDEMA2 reports
APPLICATION SITE ACNE2 reports
APPLICATION SITE DISCOLOURATION2 reports
APPLICATION SITE DRYNESS2 reports
APPLICATION SITE PRURITUS2 reports
APPLICATION SITE PUSTULES2 reports
CHEMICAL BURN2 reports
DERMATITIS ATOPIC2 reports
DERMATITIS CONTACT2 reports
DRUG HYPERSENSITIVITY2 reports
EXPOSURE TO TOXIC AGENT2 reports
EXPOSURE VIA INHALATION2 reports
FURUNCLE2 reports
HAEMATOLOGICAL MALIGNANCY2 reports
HEADACHE2 reports
LEUKAEMIA2 reports
NAUSEA2 reports
POISONING2 reports
POISONING DELIBERATE2 reports
POST INFLAMMATORY PIGMENTATION CHANGE2 reports
PRECANCEROUS CONDITION2 reports
PRODUCT CONTAMINATION2 reports
PRODUCT FORMULATION ISSUE2 reports
PRODUCT PHYSICAL CONSISTENCY ISSUE2 reports
PRODUCT USE IN UNAPPROVED INDICATION2 reports
SKIN IRRITATION2 reports
SUSPECTED PRODUCT TAMPERING2 reports
SWELLING OF EYELID2 reports
THERMAL BURN2 reports
ABDOMINAL DISTENSION1 reports
ABNORMAL WEIGHT GAIN1 reports
ACNE1 reports
ANXIETY1 reports
APPENDIX CANCER1 reports
APPLICATION SITE EXFOLIATION1 reports
APPLICATION SITE URTICARIA1 reports
APPLICATION SITE VESICLES1 reports
ARTHROPOD BITE1 reports
BLADDER CANCER1 reports
BLADDER CANCER STAGE III1 reports
BLOOD BLISTER1 reports
BLOOD PRESSURE INCREASED1 reports
BONE PAIN1 reports
BRAIN NEOPLASM1 reports
CHEMICAL BURNS OF EYE1 reports
CHEST PAIN1 reports
COELIAC DISEASE1 reports
CONDITION AGGRAVATED1 reports
CONFUSIONAL STATE1 reports
CONTUSION1 reports
DEATH1 reports
DERMATITIS1 reports
DERMATITIS ALLERGIC1 reports
DIARRHOEA1 reports
DISCOMFORT1 reports

Report Outcomes

Out of 258 classified reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE:

Serious 85.7%Non-Serious 14.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female127 (66.8%)
Male63 (33.2%)

Reports by Age

Age 326 reports
Age 65 reports
Age 665 reports
Age 384 reports
Age 414 reports
Age 594 reports
Age 604 reports
Age 73 reports
Age 113 reports
Age 213 reports
Age 303 reports
Age 333 reports
Age 353 reports
Age 623 reports
Age 92 reports
Age 142 reports
Age 152 reports
Age 192 reports
Age 242 reports
Age 342 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE?

This profile reflects 448 FDA FAERS reports that mention AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE?

Frequently reported terms in FAERS include SKIN CANCER, BASAL CELL CARCINOMA, NEOPLASM MALIGNANT, RASH, MALIGNANT MELANOMA, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE?

Labeling and FAERS entries often list Kenvue Brands LLC in connection with AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.